-> Home    -> Contact Us    -> Site Map   
  -> Search
ImmunoGen, Inc.
Company OverviewOur TAP TechnologyProduct PipelineInvestor InformationJoin Our Team
Board of Directors

  • Mitchel Sayare, Ph.D.
    Chairman of the Board


    • Mitchel Sayare, Ph.D., age 60, has been a director of ImmunoGen since 1986 and has been our Chairman of the Board since 1989. Dr. Sayare served as our Chief Executive Officer from 1986 to Dec. 31, 2008; he also served as our President from 1986 to 1992 and from 1994 to July 2008. Prior to joining ImmunoGen, he served as Vice President of Development of Xenogen from 1982 to 1985. Prior to that he was Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. Dr. Sayare holds a Ph.D. in Biochemistry from Temple University School of Medicine. Dr. Sayare is also a director of ImmuCell Corporation, in addition to a number of private companies.

  • David W. Carter
    Formerly Chairman and Chief Executive Officer, Xenogen, Inc.


    • David W. Carter, age 70, has been a director of ImmunoGen since 1997, and has served as our Lead Director since 2002. Mr. Carter founded and has served as President of DaCart, Inc., which provides consulting services to start-up and re-start biotechnology companies, since 2006. Prior to that he served as Chief Executive Officer and Chairman of Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer, from 1997 to its acquisition by Caliper Life Sciences, Inc. in 2006. Prior to that he served as Chairman of the Board, President and Chief Executive Officer of Somatix Therapy Corporation, a gene therapy company, from 1991 to its merger with Cell Genesys, Inc. in 1997. Mr. Carter is also a director of Caliper Life Sciences, Inc. and Cell Genesys, Inc.

  • Daniel M. Junius
    President and Chief Executive Officer, ImmunoGen, Inc.


    • Daniel M. Junius, age 56, has been a director of ImmunoGen since November 2008 and the Chief Executive Officer of the Company since January 1, 2009. Mr. Junius served as President and Chief Operating Officer of ImmunoGen from July 2008 to December 31, 2008, as Executive Vice President, Finance and Chief Financial Officer of ImmunoGen from July 2006 to June 2008, and as Senior Vice President, Finance and Chief Financial Officer of ImmunoGen from May 2005 to July 2006.

    Mr. Junius served as Executive Vice President and Chief Financial Officer of New England Business Service, Inc. (NEBS) from 1998 to 2004. Prior to NEBS, he served as Vice President and Chief Financial of Nashua Corporation. Mr. Junius joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming Chief Financial Officer in 1996.

  • Stephen C. McCluski
    • Formerly Senior Vice President and Chief Financial Officer, Baush & Lomb, Inc.

    Stephen C. McCluski, age 55, has been a director of ImmunoGen since April 2007. Mr. McCluski served as Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated, a manufacturer of health care products for the eye, from 1995 to his retirement in 2007. Prior to that he served in various executive capacities at Bausch & Lomb and its subsidiaries from 1989 to 1995. Mr. McCluski is also a director of Indevus Pharmaceuticals, Inc. and the James P. Wilmot Cancer Center of the University of Rochester.

  • Nicole Onetto, M.D.
    • Senior Vice President, Product Development and Chief Medical Officer, ZymoGenetics, Inc.

    Nicole Onetto, MD, age 55, has been a director of ImmunoGen since 2005. Dr. Onetto has served as Senior Vice President and Chief Medical Officer of ZymoGenetics, Inc., a biotechnology company specializing in protein therapeutics, since 2005. Prior to that she served as Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2005, and as Executive Vice President of OSI Pharmaceutical’s Oncology business from 2002 to 2003. Prior to that she served as Senior Vice President, Medical Affairs, at Gilead Sciences, Inc., a biopharmaceutical company, from 2000 to 2001. Dr. Onetto has a Doctor of Medicine degree from the University of Paris V, France.

  • Mark Skaletsky
    • President and Chief Executive Officer, Fenway Pharmaceuticals

    Mark Skaletsky, age 60, has been a director of ImmunoGen since 2000. Mr. Skaletsky has served as Chairman of the Board and Chief Executive Officer of Fenway Pharmaceuticals, Inc., a drug development company, since April 2008. Prior to that he served as Chairman of the Board and Chief Executive Officer of Trine Pharmaceuticals, Inc. (formerly Essential Therapeutics, Inc.), a drug development company, from 2001 to 2007. Prior to that he served as Chairman of the Board and Chief Executive Officer of The Althexis Company, Inc. a drug discovery company, from 2000 to its acquisition by Essential Therapeutics in 2001. Mr. Skaletsky is also a director of Alkermes, Inc., AMAG Pharmaceuticals, Inc. and Targacept, Inc.

  • Joseph J. Villafranca, Ph.D.
    Senior Vice President, Operations, Tunnell Consulting


    • Joseph J. Villafranca, Ph.D., age 64, has been a director of ImmunoGen since 2004. Dr. Villafranca has served as Senior Vice President – Operations and Principal & Practice Director, Life Sciences, of Tunnell Consulting, a consulting firm focusing on the life sciences industry, since 2006. Prior to that he served as President of Biopharmaceutical Consultants LLC from 2005 to 2006. Prior to that he served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc., a biotechnology company, from 2002 to 2005. Prior to that he served in various executive positions at Bristol-Myers Squibb Company over a period of 11 years. Dr. Villafranca holds a Ph.D. in Biochemistry/Chemistry from Purdue University and completed his postdoctoral work at the Institute for Cancer Research in Philadelphia, Pennsylvania.

  • Richard Wallace
    Formerly Senior Vice President of Research and Development at GlaxoSmithKline

    Richard J. Wallace, age 57, has been a director of ImmunoGen since November 2007. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc (GSK), a pharmaceutical company, from 2004 to his retirement in 2008. Prior to that he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company and seven years at Johnson & Johnson (in assignments spanning marketing, sales, manufacturing and general management). Mr. Wallace is also a director of Avigen, Inc., Clinical Data, Inc. and Bridgehead International Ltd.


© 2009 ImmunoGen, Inc. | Privacy Policy | Usage Policy
Last updated January 1, 2009